New opportunities may also arise using 2-PMPA as a nephron-protective strategy in PSMA-targeted prostate cancer radiotherapy (Kratochwil et al., 2015; Chatalic et al., 2016) or use of 2-PMPA as an inhibitor of cytosolic carboxypeptidases (Wang et al., 2020). The gene discussed is FOLH1; the disease is prostate carcinoma.